Rallybio Corp

NASDAQ:RLYBUnited States

Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.

Contact Information

Headquarters

234 CHURCH STREET, SUITE 1020NEW HAVEN, CT, United States 06510

Phone

203-859-3820

Fax

302-636-5454

Executives

Executive Chairman of the Board

Martin Mackay

President, Chief Executive Officer, Director

Stephen Uden

Chief Financial Officer, Treasurer

Jonathan Lieber

Chief Medical Officer

Steven Ryder

Independent Director

Helen Boudreau